A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).

Ishiguro, Hiroshi

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). [electronic resource] - Cancer medicine Dec 2017 - 2909-2917 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

2045-7634

10.1002/cam4.1258 doi


Adult
Aged
Antigens, CD34--blood
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Breast Neoplasms--drug therapy
Camptothecin--administration & dosage
Disease-Free Survival
Drug Administration Schedule
Drug Combinations
Endothelial Progenitor Cells--drug effects
Female
Gene Frequency
Glucuronosyltransferase--genetics
Heterozygote
Homozygote
Humans
Irinotecan
Japan
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Oxonic Acid--administration & dosage
Pharmacogenetics
Pharmacogenomic Variants
Phenotype
Tegafur--administration & dosage
Treatment Outcome